dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Liu, Geoffrey |
dc.contributor.author | Stratmann, Jan |
dc.contributor.author | Ou, Sai-Hong |
dc.contributor.author | Mok, Tony |
dc.contributor.author | MAZIERES, JULIEN |
dc.contributor.author | Bauer, Todd |
dc.contributor.author | FELIP, ENRIQUETA |
dc.date.accessioned | 2024-04-09T09:57:43Z |
dc.date.available | 2024-04-09T09:57:43Z |
dc.date.issued | 2024-03-14 |
dc.identifier.citation | Liu G, Mazieres J, Stratmann J, Ignatius Ou SH, Mok T, Grizzard M, et al. A pragmatic guide for management of adverse events associated with lorlatinib. Lung Cancer. 2024 Mar 14;191:107535. |
dc.identifier.issn | 0169-5002 |
dc.identifier.uri | https://hdl.handle.net/11351/11297 |
dc.description | Limfoma quinasa anaplàstic; Carcinoma; Inhibidors de la tirosina cinasa |
dc.description.sponsorship | Development of this report was funded by Pfizer. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Lung Cancer;191 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Proteïnes quinases - Inhibidors - Ús terapèutic - Efectes secundaris |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Protein Kinase Inhibitors |
dc.subject.mesh | /adverse effects |
dc.title | A pragmatic guide for management of adverse events associated with lorlatinib |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.lungcan.2024.107535 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inhibidores de proteínas cinasas |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://doi.org/10.1016/j.lungcan.2024.107535 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Liu G] Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. [Mazieres J] Thoracic Oncology Department, Toulouse University Hospital, Toulouse, France. [Stratmann J] Department of Medicine II, Hematology/Oncology, University Hospital Frankfurt, Frankfurt, and National Network Genomic Medicine Lung Cancer, Cologne, Germany. [Ignatius Ou SH] Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA. [Mok T] State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong Special Administrative Region of China, China. [Grizzard M] Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 38554546 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |